https://www.live-feeds.com/feed/vera-kidney-drug-trutakna-shows-strong-final-results-in-phase-3-trialContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/vera-kidney-drug-trutakna-shows-strong-final-results-in-phase-3-trialhttps://www.live-feeds.com/feed/vera-kidney-drug-trutakna-shows-strong-final-results-in-phase-3-trial#u72327Thu, 17 Sep 2026 06:40:30 +0000Vera Therapeutics announced that its drug Trutakna (atacicept-vymj) stabilized kidney function and prevented disease progression in adults with primary IgA nephropathy. Final efficacy analysis from the two-year ORIGIN 3 Phase 3 trial shows the drug reduced the risk of IgAN progression by 76%. These results position the treatment for full regulatory approval. The data confirms that Trutakna stabilized eGFR and reduced the rate of kidney function decline over the 104-week study period.Why it mattersIgA nephropathy is a kidney disease that can lead to progressive renal failure. Trutakna aims to s